The trial is to investigate the efficacy, effectiveness, safety and pharmacokinetics of Posidur in 305 patients undergoing a variety of general abdominal surgical procedures.
Durect expects to report top-line data from the BESST trial in the fourth quarter of 2011.
Durect has licensed Posidur to Hospira for commercialization in the US and Canada.